reference/8075561

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8075561

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
issn	1742-4690
issueIdentifier	1
pageRange	21-
publicationName	Retrovirology
startingPage	21
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a88f7782e8f1b29fc485717798325054
bibliographicCitation	Loret EP, Darque A, Jouve E, Loret EA, Nicolino-Brunet C, Morange S, Castanier E, Casanova J, Caloustian C, Bornet C, Coussirou J, Boussetta J, Couallier V, Blin O, Dussol B, Ravaux I. Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial. Retrovirology. 2016 May 09;13(1):35. PMID: 27160192; PMCID: PMC4862173.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89d89c411857ccf7338916655812e26c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2879f324c0b5b238d902736ed4dab784 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d66f1855085f199b8bb3c7bbbd974775 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4873-6522 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4a78294e616e6a765675000fbee144b5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0593c3fcd078a05aa3137962f4e4fb26 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9bc19cc7e434a8a3b151d6a11ab69048 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_74b7e11ca143c1f869e505091a4498a9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f8fbe02f7f6545af0bdd14de9c69063 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5f54ab1f4ae63e2dcd82af23f3d09be2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e62b25c61bca905e5dd82ec937689a1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e8068629e63f8aab218ee5759d6309b5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_001bdc7cf272231c73e2ed878d49746a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_80c21223c9544d2530bc0f6488330260 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8d0bbf9d7fa704b1f7471ed03069a26d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_49ccf702944cd43ffba40bc6734a2f15 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3b12476f3800976e7bce8a2f37482458
date	2016-05-09^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC4862173 https://pubmed.ncbi.nlm.nih.gov/27036656 https://doi.org/10.1186/s12977-016-0264-y https://doi.org/10.1186/s12977-016-0251-3 https://pubmed.ncbi.nlm.nih.gov/27160192
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/31946 https://portal.issn.org/resource/ISSN/1742-4690
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://scigraph.springernature.com/ https://www.crossref.org/
title	Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial
discusses	http://id.nlm.nih.gov/mesh/M0025741 http://id.nlm.nih.gov/mesh/M0024080 http://id.nlm.nih.gov/mesh/M0446823 http://id.nlm.nih.gov/mesh/M0006695 http://id.nlm.nih.gov/mesh/M0019224
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D015658Q000628 http://id.nlm.nih.gov/mesh/D044966Q000627 http://id.nlm.nih.gov/mesh/D019562 http://id.nlm.nih.gov/mesh/D016915Q000276 http://id.nlm.nih.gov/mesh/D015497Q000276 http://id.nlm.nih.gov/mesh/D054322Q000276
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D012367Q000097 http://id.nlm.nih.gov/mesh/D007271 http://id.nlm.nih.gov/mesh/D004279Q000097 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D016915Q000008 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D006801

Showing number of triples: 1 to 60 of 60.